Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism

Movement Disorders

Volumn 24, Issue 7, 2009, Pages 1080-1084

  Paus, Sebastian ^a   Gadow, Franziska ^a   Knapp, Michael ^a   Klein, Christine ^b   Klockgether, Thomas ^a   Wüllner, Ullrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

DRD3 Ser9Gly; Dyskinesia; Levodopa; Motor complications; Parkinson's disease

Indexed keywords

DOPAMINE 3 RECEPTOR; GLYCINE; LEVODOPA; SERINE;

ADULT; AGE DISTRIBUTION; AKINESIA; ARTICLE; CHOREA; DISEASE DURATION; DYSKINESIA; DYSTONIA; FEMALE; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COMMUNITY NETWORKS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; GLYCINE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D3; REGRESSION ANALYSIS; SERINE;

EID: 67651154469     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22508     Document Type: Article

References (24)

1. Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55(Suppl 6):S2-S6.
2. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
4. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20(Suppl 11): S11-S16.
5. Lyons KE, Hubble JP, Tröster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin Neuropharmacol 1998; 21:118-121.
6. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005; 62:601-605.
7. Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. Pharmacogenomics J 2004;4: 291-306.
8. Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999;53:1425-1430.
9. Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001;56:1757-1759.
10. Kaiser R, Hofer A, Grapengiesser A, et al. L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003;60:1750-1755.
11. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-3367.
12. Van Kampen JM, Stoessl AJ. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 2003;116:307-314.
13. Bézard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
14. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.
15. De Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448-456.
16. Lannfelt L, Sokoloff P, Martres M-P, et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992;2:249-256.
17. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996;225:1068-1072.
18. Eggert K, Wüllner U, Antony G, et al. Data protection in biomaterial banks for Parkinson's disease research: the model GEPARD (Gene Bank Parkinson's Disease Germany). Mov Disord 2007;22:611-618.
19. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
20. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
21. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
22. Segman RH, Heresco-Levy U, Yakir A, et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002;51:261-263.
23. Klein C. Implications of genetics on the diagnosis and care patients with Parkinson disease. Arch Neurol 2006;63:328-334.
24. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol postmenopausal PD patients: a crossover study. Neurology 1999; 53:91-95.